Decreased urinary polyamines in patients with psoriasis treated with etretinate

R. C. Grekin, C. N. Ellis, N. G. Goldstein, Neil Swanson, T. F. Anderson, E. A. Duell, J. J. Voorhees

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Oral administration of the aromatic retinoid etretinate is effective therapy for psoriasis and other epidermal hyperproliferative disorders. Since polyamine metabolism is known to be important in cell growth and differentiation, we measured urinary levels of the polyamines putrescine, spermidine, and spermine as a reflection of cutaneous polyamine metabolism in 19 psoriatic patients treated with etretinate for 16 weeks. Using thin-layer chromatography, polyamine determinations were performed on urine collected pretherapy, during therapy, and 8 weeks after therapy was concluded. Good to excellent clearing of psoriasis occurred in 18 of 19 patients. All urinary polyamines showed a downward trend in the first week of therapy, prior to significant clinical improvement. At week 16 of therapy, the greatest reduction in mean urinary polyamine content occurred. Mean putrescine levels decreased from pretherapy to week 16 by 27% (p <0.001), mean spermidine values fell by 34% (p <0.001), and mean spermine levels declined by 37% (p = 0.005). These data are consistent with the hypothesis that etretinate inhibits polyamine biosynthesis.

Original languageEnglish (US)
Pages (from-to)181-184
Number of pages4
JournalJournal of Investigative Dermatology
Volume80
Issue number3
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Etretinate
Polyamines
Psoriasis
Putrescine
Spermidine
Spermine
Metabolism
Therapeutics
Thin layer chromatography
Biosynthesis
Retinoids
Cell growth
Thin Layer Chromatography
Oral Administration
Cell Differentiation
Urine
Skin
Growth

ASJC Scopus subject areas

  • Dermatology

Cite this

Grekin, R. C., Ellis, C. N., Goldstein, N. G., Swanson, N., Anderson, T. F., Duell, E. A., & Voorhees, J. J. (1983). Decreased urinary polyamines in patients with psoriasis treated with etretinate. Journal of Investigative Dermatology, 80(3), 181-184. https://doi.org/10.1111/1523-1747.ep12533435

Decreased urinary polyamines in patients with psoriasis treated with etretinate. / Grekin, R. C.; Ellis, C. N.; Goldstein, N. G.; Swanson, Neil; Anderson, T. F.; Duell, E. A.; Voorhees, J. J.

In: Journal of Investigative Dermatology, Vol. 80, No. 3, 1983, p. 181-184.

Research output: Contribution to journalArticle

Grekin, RC, Ellis, CN, Goldstein, NG, Swanson, N, Anderson, TF, Duell, EA & Voorhees, JJ 1983, 'Decreased urinary polyamines in patients with psoriasis treated with etretinate', Journal of Investigative Dermatology, vol. 80, no. 3, pp. 181-184. https://doi.org/10.1111/1523-1747.ep12533435
Grekin, R. C. ; Ellis, C. N. ; Goldstein, N. G. ; Swanson, Neil ; Anderson, T. F. ; Duell, E. A. ; Voorhees, J. J. / Decreased urinary polyamines in patients with psoriasis treated with etretinate. In: Journal of Investigative Dermatology. 1983 ; Vol. 80, No. 3. pp. 181-184.
@article{9b3c8f90071943959676826a14e9e15a,
title = "Decreased urinary polyamines in patients with psoriasis treated with etretinate",
abstract = "Oral administration of the aromatic retinoid etretinate is effective therapy for psoriasis and other epidermal hyperproliferative disorders. Since polyamine metabolism is known to be important in cell growth and differentiation, we measured urinary levels of the polyamines putrescine, spermidine, and spermine as a reflection of cutaneous polyamine metabolism in 19 psoriatic patients treated with etretinate for 16 weeks. Using thin-layer chromatography, polyamine determinations were performed on urine collected pretherapy, during therapy, and 8 weeks after therapy was concluded. Good to excellent clearing of psoriasis occurred in 18 of 19 patients. All urinary polyamines showed a downward trend in the first week of therapy, prior to significant clinical improvement. At week 16 of therapy, the greatest reduction in mean urinary polyamine content occurred. Mean putrescine levels decreased from pretherapy to week 16 by 27{\%} (p <0.001), mean spermidine values fell by 34{\%} (p <0.001), and mean spermine levels declined by 37{\%} (p = 0.005). These data are consistent with the hypothesis that etretinate inhibits polyamine biosynthesis.",
author = "Grekin, {R. C.} and Ellis, {C. N.} and Goldstein, {N. G.} and Neil Swanson and Anderson, {T. F.} and Duell, {E. A.} and Voorhees, {J. J.}",
year = "1983",
doi = "10.1111/1523-1747.ep12533435",
language = "English (US)",
volume = "80",
pages = "181--184",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Decreased urinary polyamines in patients with psoriasis treated with etretinate

AU - Grekin, R. C.

AU - Ellis, C. N.

AU - Goldstein, N. G.

AU - Swanson, Neil

AU - Anderson, T. F.

AU - Duell, E. A.

AU - Voorhees, J. J.

PY - 1983

Y1 - 1983

N2 - Oral administration of the aromatic retinoid etretinate is effective therapy for psoriasis and other epidermal hyperproliferative disorders. Since polyamine metabolism is known to be important in cell growth and differentiation, we measured urinary levels of the polyamines putrescine, spermidine, and spermine as a reflection of cutaneous polyamine metabolism in 19 psoriatic patients treated with etretinate for 16 weeks. Using thin-layer chromatography, polyamine determinations were performed on urine collected pretherapy, during therapy, and 8 weeks after therapy was concluded. Good to excellent clearing of psoriasis occurred in 18 of 19 patients. All urinary polyamines showed a downward trend in the first week of therapy, prior to significant clinical improvement. At week 16 of therapy, the greatest reduction in mean urinary polyamine content occurred. Mean putrescine levels decreased from pretherapy to week 16 by 27% (p <0.001), mean spermidine values fell by 34% (p <0.001), and mean spermine levels declined by 37% (p = 0.005). These data are consistent with the hypothesis that etretinate inhibits polyamine biosynthesis.

AB - Oral administration of the aromatic retinoid etretinate is effective therapy for psoriasis and other epidermal hyperproliferative disorders. Since polyamine metabolism is known to be important in cell growth and differentiation, we measured urinary levels of the polyamines putrescine, spermidine, and spermine as a reflection of cutaneous polyamine metabolism in 19 psoriatic patients treated with etretinate for 16 weeks. Using thin-layer chromatography, polyamine determinations were performed on urine collected pretherapy, during therapy, and 8 weeks after therapy was concluded. Good to excellent clearing of psoriasis occurred in 18 of 19 patients. All urinary polyamines showed a downward trend in the first week of therapy, prior to significant clinical improvement. At week 16 of therapy, the greatest reduction in mean urinary polyamine content occurred. Mean putrescine levels decreased from pretherapy to week 16 by 27% (p <0.001), mean spermidine values fell by 34% (p <0.001), and mean spermine levels declined by 37% (p = 0.005). These data are consistent with the hypothesis that etretinate inhibits polyamine biosynthesis.

UR - http://www.scopus.com/inward/record.url?scp=0020665347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020665347&partnerID=8YFLogxK

U2 - 10.1111/1523-1747.ep12533435

DO - 10.1111/1523-1747.ep12533435

M3 - Article

VL - 80

SP - 181

EP - 184

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 3

ER -